{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044006","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.521303+00:00","generated_at":"2026-05-30T03:41:46.012364+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in","bullets":["Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.","LP-300 Harmonic trial: 86% clinical benefit rate, 43% objective response in 7-patient lead-in; expanded to Japan and Taiwan.","LP-184 Phase 1a: 9 cohorts dosed, no DLTs; FDA Fast Track for GBM; Phase 1b/2a expected early 2025.","LP-284 Phase 1a: fourth cohort dosing, no DLTs; additional hematology sites planned; potential Phase 1b/2 by mid-2025.","R&D expenses $3.7M (up from $2.2M); G&A $1.5M ($1.3M); 10.8M shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044006","json":"https://secwatch.observer/filing/0001493152-24-044006.json","markdown":"https://secwatch.observer/filing/0001493152-24-044006.md","text":"https://secwatch.observer/filing/0001493152-24-044006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224044006/0001493152-24-044006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224044006/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:41:46.012364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}